198 related articles for article (PubMed ID: 31326985)
1. A practical composite risk score for the development of Haemolytic Uraemic Syndrome from Shiga toxin-producing Escherichia coli.
Hamilton D; Cullinan J
Eur J Public Health; 2019 Oct; 29(5):861-868. PubMed ID: 31326985
[TBL] [Abstract][Full Text] [Related]
2. Estimating true incidence of O157 and non-O157 Shiga toxin-producing Escherichia coli illness in Germany based on notification data of haemolytic uraemic syndrome.
Kuehne A; Bouwknegt M; Havelaar A; Gilsdorf A; Hoyer P; Stark K; Werber D;
Epidemiol Infect; 2016 Nov; 144(15):3305-3315. PubMed ID: 27468812
[TBL] [Abstract][Full Text] [Related]
3. Risk of haemolytic uraemic syndrome caused by shiga-toxin-producing Escherichia coli infection in adult women in Japan.
Fujii J; Mizoue T; Kita T; Kishimoto H; Joh K; Nakada Y; Ugajin S; Naya Y; Nakamura T; Tada Y; Okabe N; Maruyama Y; Saitoh K; Kurozawa Y
Epidemiol Infect; 2016 Apr; 144(5):952-61. PubMed ID: 26470913
[TBL] [Abstract][Full Text] [Related]
4. Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network.
Ardissino G; Vignati C; Masia C; Capone V; Colombo R; Tel F; Daprai L; Testa S; Dodaro A; Paglialonga F; Luini M; Brigotti M; Picicco D; Baldioli C; Pagani F; Ceruti R; Tommasi P; Possenti I; Cresseri D; Consonni D; Montini G; Arghittu M;
J Pediatr; 2021 Oct; 237():34-40.e1. PubMed ID: 34197890
[TBL] [Abstract][Full Text] [Related]
5. Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)-producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland.
Rastawicki W; Śmietańska K; Rokosz-Chudziak N; Wołkowicz T
Lett Appl Microbiol; 2020 Jun; 70(6):440-446. PubMed ID: 32270510
[TBL] [Abstract][Full Text] [Related]
6. Shiga toxin-producing escherichia coli infections in Norway, 1992-2012: characterization of isolates and identification of risk factors for haemolytic uremic syndrome.
Brandal LT; Wester AL; Lange H; Løbersli I; Lindstedt BA; Vold L; Kapperud G
BMC Infect Dis; 2015 Aug; 15():324. PubMed ID: 26259588
[TBL] [Abstract][Full Text] [Related]
7. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection.
Tajiri H; Nishi J; Ushijima K; Shimizu T; Ishige T; Shimizu M; Tanaka H; Brooks S
Int J Antimicrob Agents; 2015 Nov; 46(5):586-9. PubMed ID: 26391378
[TBL] [Abstract][Full Text] [Related]
8. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview.
Kakoullis L; Papachristodoulou E; Chra P; Panos G
J Infect; 2019 Aug; 79(2):75-94. PubMed ID: 31150744
[TBL] [Abstract][Full Text] [Related]
9. Haemolytic uraemic syndrome in children England, Wales, Northern Ireland, and Ireland: A prospective cohort study.
Byrne L; Douglas A; Launders N; Godbole G; Lynn R; Inward C; Jenkins C
Epidemiol Infect; 2023 Sep; 151():e160. PubMed ID: 37655611
[TBL] [Abstract][Full Text] [Related]
10. An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values.
López EL; Contrini MM; Glatstein E; Ayala SG; Santoro R; Ezcurra G; Teplitz E; Matsumoto Y; Sato H; Sakai K; Katsuura Y; Hoshide S; Morita T; Harning R; Brookman S
Pediatr Infect Dis J; 2012 Jan; 31(1):20-4. PubMed ID: 21829137
[TBL] [Abstract][Full Text] [Related]
11. Soluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic syndrome: a case-control study.
Doulgere J; Otto B; Nassour M; Wolters-Eisfeld G; Rohde H; Magnus T; Wagener C; Streichert T
BMJ Open; 2015 Mar; 5(3):e005659. PubMed ID: 25757942
[TBL] [Abstract][Full Text] [Related]
12. Virulence factors of Shiga toxin-producing Escherichia coli and the risk of developing haemolytic uraemic syndrome in Norway, 1992-2013.
Naseer U; Løbersli I; Hindrum M; Bruvik T; Brandal LT
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1613-1620. PubMed ID: 28391537
[TBL] [Abstract][Full Text] [Related]
13. Diarrhoea-associated haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infections in New Zealand children: Clinical features and short-term complications from a 23-year cohort study.
Wong W; Prestidge C; Dickens A; Ronaldson J
J Paediatr Child Health; 2023 Mar; 59(3):493-498. PubMed ID: 36655863
[TBL] [Abstract][Full Text] [Related]
14. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.
Ardissino G; Possenti I; Vignati C; Daprai L; Capone V; Brigotti M; Luini MV; Consonni D; Montini G
Pediatr Nephrol; 2020 Oct; 35(10):1997-2001. PubMed ID: 32734345
[TBL] [Abstract][Full Text] [Related]
15. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome.
Ylinen E; Salmenlinna S; Halkilahti J; Jahnukainen T; Korhonen L; Virkkala T; Rimhanen-Finne R; Nuutinen M; Kataja J; Arikoski P; Linkosalo L; Bai X; Matussek A; Jalanko H; Saxén H
Pediatr Nephrol; 2020 Sep; 35(9):1749-1759. PubMed ID: 32323005
[TBL] [Abstract][Full Text] [Related]
16. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
Monet-Didailler C; Chevallier A; Godron-Dubrasquet A; Allard L; Delmas Y; Contin-Bordes C; Brissaud O; Llanas B; Harambat J
Nephrol Dial Transplant; 2020 Dec; 35(12):2147-2153. PubMed ID: 31411695
[TBL] [Abstract][Full Text] [Related]
17. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection.
Bruyand M; Mariani-Kurkdjian P; Gouali M; de Valk H; King LA; Le Hello S; Bonacorsi S; Loirat C
Med Mal Infect; 2018 May; 48(3):167-174. PubMed ID: 29054297
[TBL] [Abstract][Full Text] [Related]
18. Desperately seeking diarrhoea: outbreak of haemolytic uraemic syndrome caused by emerging sorbitol-fermenting shiga toxin-producing Escherichia coli O157:H-, Germany, 2009.
Nielsen S; Frank C; Fruth A; Spode A; Prager R; Graff A; Plenge-Bönig A; Loos S; Lütgehetmann M; Kemper MJ; Müller-Wiefel DE; Werber D
Zoonoses Public Health; 2011 Dec; 58(8):567-72. PubMed ID: 21824358
[TBL] [Abstract][Full Text] [Related]
19. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.
Kielstein JT; Beutel G; Fleig S; Steinhoff J; Meyer TN; Hafer C; Kuhlmann U; Bramstedt J; Panzer U; Vischedyk M; Busch V; Ries W; Mitzner S; Mees S; Stracke S; Nürnberger J; Gerke P; Wiesner M; Sucke B; Abu-Tair M; Kribben A; Klause N; Schindler R; Merkel F; Schnatter S; Dorresteijn EM; Samuelsson O; Brunkhorst R;
Nephrol Dial Transplant; 2012 Oct; 27(10):3807-15. PubMed ID: 23114903
[TBL] [Abstract][Full Text] [Related]
20. Interventions for Shiga toxin-producing Escherichia coli gastroenteritis and risk of hemolytic uremic syndrome: A population-based matched case control study.
Myojin S; Pak K; Sako M; Kobayashi T; Takahashi T; Sunagawa T; Tsuboi N; Ishikura K; Kubota M; Kubota M; Igarashi T; Morioka I; Miyairi I
PLoS One; 2022; 17(2):e0263349. PubMed ID: 35120154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
